Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment | Zendy

Aaron F. Carlin | Zendy; Alex E. Clark | Zendy; Antoine Chaillon | Zendy; Aaron F. Garretson | Zendy; William A. Bray | Zendy; Magali Porrachia | Zendy; AsherLev T Santos | Zendy; Tariq M. Rana | Zendy; Davey M. Smith | Zendy

Open Access

Virologic and Immunologic Characterization of Coronavirus Disease 2019 Recrudescence After Nirmatrelvir/Ritonavir Treatment

Author(s) -

Aaron F. Carlin,

Alex E. Clark,

Antoine Chaillon,

Aaron F. Garretson,

William A. Bray,

Magali Porrachia,

AsherLev T Santos,

Tariq M. Rana,

Davey M. Smith

Publication year - 2022

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciac496

Subject(s) - medicine , virology , immunology , coronavirus , ritonavir , covid-19 , antibody , disease , virus , infectious disease (medical specialty) , viral load , outbreak , antiretroviral therapy

We isolated a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.2 variant from a person with coronavirus disease 2019 recrudescence after nirmatrelvir/ritonavir treatment. Antiviral sensitivity and neutralizing antibody testing were performed with both parental SARS-CoV-2 and multiple variants of concern. We found that neither nirmatrelvir resistance nor absence of neutralizing immunity was a likely cause of the recrudescence.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research